COMPASS Pathways (CMPS) Q1 2025 earnings summary

Executive summary

• Completed dosing of all participants in Part A of the pivotal phase III COMP005 trial for TRD; six-week top-line results expected in late June 2025.

• Reported Q1 2025 net loss of $17.9 million, a significant improvement from $35.2 million in Q1 2024, mainly due to a $19.5 million non-cash gain on warrant liabilities.

• Cash and cash equivalents increased to $260.1 million as of March 31, 2025, up from $165.1 million at year-end 2024, supported by $140.4 million net cash raised in Q1 2025.

• Phase 2 open-label study in PTSD showed COMP360 was well tolerated with rapid and durable symptom improvement; late-stage PTSD program in design phase.

• No therapeutic candidates approved for sale; operations funded by equity, debt, and warrant exercises.

Financial highlights

• Net loss for Q1 2025 was $17.9 million ($0.20 per share basic), compared to $35.2 million ($0.55 per share) in Q1 2024.

• Research and development expenses rose to $30.9 million from $24.9 million year-over-year, driven by late-stage clinical trial activity.

• General and administrative expenses increased to $18.7 million from $13.7 million, mainly due to financing and professional service costs.

• Cash used in operations for Q1 2025: $45.7 million; projected full-year 2025 operational cash use: $120–$145 million.

• Weighted average shares outstanding increased to 89.2 million (basic) in Q1 2025 due to new equity issuance.

Outlook and guidance

• Cash position expected to fund operations through the planned 26-week COMP006 data readout in H2 2026.

• Three major data readouts anticipated over the next 18 months, starting with COMP005 six-week results in late June 2025.

• Substantial additional funding will be required for commercialization and further development; future viability depends on ability to raise capital.

• Research and development expenses expected to increase as Phase 3 TRD program progresses and late-stage PTSD program is initiated.